Carotid atherosclerosis and cardiovascular risk factors in hemodialysis and peritoneal dialysis patients

Clinical Biochemistry

Volumn 40, Issue 18, 2007, Pages 1361-1366

  Yilmaz, Fatma Meriç ^a   Akay, Hatice ^a   Duranay, Murat ^a   Yilmaz, Gülsen ^a   Öztekin, Pelin Seher ^b   Koşar, Uǧur ^b   Tekeli, Nurçin ^a   Altay, Mustafa ^a   Parpucu, Hülya ^a   Yücel, Doǧan ^a  

^a MINISTRY OF HEALTH   (Turkey)

^b ANKARA NUMUNE HOSPITAL   (Turkey)

Author keywords

Cardiovascular diseases; Carotid atherosclerosis; Hemodialysis; Homocysteine; hs CRP; Lipoprotein(a); Peritoneal dialysis; Sialic acid; Thiobarbituric acid reactive substances

Indexed keywords

ALPHA TOCOPHEROL; BILIRUBIN; C REACTIVE PROTEIN; HOMOCYSTEINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RETINOL; SIALIC ACID; THIOBARBITURIC ACID;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTERY INTIMA; ARTICLE; B SCAN; BRAIN ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMODIALYSIS; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM;

ADULT; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAROTID ARTERY DISEASES; FEMALE; HOMOCYSTEINE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; N-ACETYLNEURAMINIC ACID; PERITONEAL DIALYSIS; RENAL DIALYSIS; RISK FACTORS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TUNICA INTIMA;

EID: 36348979392     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.07.017     Document Type: Article

References (44)

1. Lindner A., Charra B., Sherrard D.J., and Scribner B.H. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N. Engl. J. Med. 290 (1974) 697-701
2. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32 (1998) 112-119
3. Cases A., Vera M., and Lopez G.J.M. Cardiovascular risk in patients with chronic renal failure. Nefrologia 22 (2002) 68-74
4. Bayes B., Pastor C., Bonal J., et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol. Dial. Transplant. 18 (2003) 106-112
5. Okhuma T., Minagawa T., Takada N., Ohno M., Oda H., and Ohashi H. C-Reactive protein, lipoprotein(a), homocysteine, and male sex contribute to carotid atherosclerosis in peritoneal dialysis patients. Am. J. Kidney Dis. 42 (2003) 355-361
6. Durand P., Prost M., Loreau N., Lussier-Cacan S., and Blache D. Impaired homocysteine metabolism and atherothrombotic disease. Lab. Invest. 81 (2001) 645-672
7. Bostom A.G., Silbershatz H., Rosenberg I.H., et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch. Intern. Med. 159 (1999) 1077-1080
8. Yi{dotless}lmaz F.M., Yi{dotless}lmaz G., Duranay M., et al. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Scand. J. Clin. Lab. Invest. 65 (2005) 739-745
9. Yao E.H., Yu Y., and Fukuda N. Oxidative stress on progenitor and stem cells in cardiovascular diseases. Curr. Pharm. Biotechnol. 7 (2006) 101-108
10. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4 hydroxynoneal malondialdehyde and related aldehydes. Free Radic. Biol. Med. 62 (1991) 81-128
11. Karatas F., Karatepe M., and Baysar A. Determination of free malondialdehyde in human serum by high performance liquid chromatography. Anal. Biochem. 311 (2002) 76-79
12. Matsuura E., Kobayashi K., Tabuchi M., and Lopez L.R. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog. Lipid Res. 45 (2006) 466-486
13. Samouilidou E., Grapsa E., Karpouza A., and Lagouranis A. Reactive oxygen metabolites: a link between oxidative stress and inflammation in patients on hemodialysis. Blood Purif. 25 (2007) 175-178
14. Uzum A., Toprak O., Gumustas M.K., Ciftci S., and Sen S. Effect of vitamin E therapy on oxidative stress and erythrocyte osmotic fragility in patients on peritoneal dialysis and hemodialysis. J. Nephrol. 19 (2006) 739-745
15. Taki K., Takayama F., Tsuruta Y., and Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int. 70 (2006) 218-224
16. Uterman G. The mysteries of lipoprotein(a). Science 246 (1989) 904-916
17. Ohashi H., Oda H., Ohno M., Watanabe S., and Sakata S. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int. Suppl. 71 (1999) 242-244
18. Iliescu E.A., Marcovina S.M., Morton A.R., Lam M., and Koschinsky M.L. Apolipoprotein a phenotype and lipoprotein a level predict peritoneal dialysis patient mortality. Perit. Dial. Int. 22 (2002) 492-499
19. Lindberg G., Eklund G., Gullberg B., et al. Serum sialic acid concentration and cardiovascular mortality. BMJ 302 (1991) 143-146
20. Serdar Z., Yesilbursa D., Dirican M., Sarandol E., and Serdar A. Sialic acid and oxidizability of lipid and proteins and antioxidant status in patients with coronary artery disease. Cell Biochem. Funct. (2006) [electronic publication ahead of print]
21. Ozben T., Nacitarhan S., and Tuncer N. Elevated serum and urine sialic acid in renal diseases. Ann. Clin. Biochem. 28 (1991) 44-48
22. Afzali B., Bakri R.S., Bharma-Ariza P., et al. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. J. Nephrol. 16 (2003) 540-545
23. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
24. Svennerholm L. Quantitative estimation of sialic acids. Biophys. Acta 24 (1957) 604-611
25. Hunter M.I.S., Nlemadim B.C., and Davidson D.L.W. Lipid peroxidation products and antioxidant proteins in plasma and cerebrospinal fluids from multiple sclerosis patients. Neurochem. Res. 10 (1985) 1645-1652
26. Handa N., Matsumoto M., Maeda H., et al. Ultrasonic evaluation of early carotid atherosclerosis. Stroke 21 (1990) 1567-1572
27. Blacher J., Guerin A.P., Pannier B., Marchais S.J., and London G.M. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38 (2001) 938-942
28. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., and Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 18 (2003) 1731-1740
29. Nishizawa Y., Shoji T., Maekawa K., et al. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis. 41 (2003) 76-79
30. Zoccali C., Benedetto F.A., Maas R., et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol. 13 (2002) 490-496
31. Ebrahim S., Papacosta O., Whincup P., et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: The British Regional Heart Study. Stroke 30 (1999) 841-850
32. Malatino L.S., Mallamaci F., Benedetto F.A., et al. Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. Am. J. Kidney Dis. 36 (2000) 945-952
33. Sitzer M., Markus H.S., Mendall M.A., Liehr R., Knorr U., and Steinmetz H. C-reactive protein and carotid intimal medial thickness in a community population. J. Cardiovasc. Risk 9 (2002) 97-103
34. Borazan A., Aydemir S., Sert M., and Yilmaz A. The effects of hemodialysis and peritoneal dialysis on serum homocysteine and C-reactive protein levels. Mediat. Inflamm. 13 (2004) 361-364
35. Samouilidou E.C., Grapsa E.J., Kakavas I., Lagouranis A., and Agrogiannis B. Oxidative stress markers and C-reactive protein in end-stage renal failure patients on dialysis. Int. Urol. Nephrol. 35 (2003) 393-397
36. Rastam L., Lindberg G., Folsom A.R., Burke G.L., Nilsson-Ehle P., and Lundblad A. Association between serum sialic acid concentration and carotid atherosclerosis measured by B-mode ultrasound. Int. J. Epidemiol. 25 (1996) 953-958
37. Samouilidou E., and Grapsa E. Effect of dialysis on plasma total antioxidant capacity and lipid peroxidation products in patients with end-stage renal failure. Blood Purif. 21 (2003) 209-212
38. Usberti M., Gerardi G.M., Gazzotti R.M., et al. Oxidative stress and cardiovascular disease in dialyzed patients. Nephron 91 (2002) 25-33
39. Papagianni A., Kalovoulos M., Kirmizis D., et al. Carotid atherosclerosis is associated with inflammation and endothelial cell adhesion molecules in chronic haemodialysis patients. Nephrol. Dial. Transplant. 18 (2003) 113-119
40. Schwertner H.A., Jackson W.G., and Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin. Chem. 40 (1994) 18-23
41. Hopkins P.N., Wu L.L., Hunt S.C., James B.C., Vincent G.M., and Williams R.R. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler Thromb. Vasc. Biol. 16 (1996) 250-255
42. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., and Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science 235 (1987) 1043-1046
43. Stocker R., Glaser A.N., and Ames B.N. Antioxidant activity of albumin-bound bilirubin. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 5918-5922
44. Neuzil J., and Stocker R. Free and albumin-bound bilirubin are efficient co-antioxidants for α-tocopherol, inhibiting plasma and low density lipoprotein peroxidation. J. Biol. Chem. 269 (1994) 16712-16719